Young-onset acromegaly and gigantism: Causes and clinical features of growth hormone overproduction


  • Raquel Vaz de Castro Serviço de Endocrinologia, Diabetes e Metabolismo Hospital de Santa Maria, CHULN – EPE, Lisboa
  • Joana Faustino epartment of Pediatrics, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central
  • Florbela Ferreira Department of Endocrinology, Diabetes and Metabolism, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte
  • Lurdes Sampaio Pediatric Endocrinology Unit, Department of Pediatrics Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte



acromegaly, gigantism, cause, clinical feature


Depending on the age of onset, the excessive release of growth hormone (GH) − most commonly by a pituitary tumor − and subsequently of insulin-like growth factor 1 (IGF1) can cause acromegaly and gigantism.
The purpose of this study was to describe the clinical manifestations and main known causes of GH overproduction.
GH-releasing hormone and IGF1 can result in a series of physical traits and comorbidities due to hormonal imbalance and somatic overgrowth. To date, several syndromes and genetic mutations have been linked to the etiology of acromegaly.


Download data is not yet available.


Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Primers 2019; 5(1):20. doi:

Rostomyan L, Daly AF, Beckers A. Pituitary gigantism: Causes and clinical characteristics. Ann Endocrinol (Paris) 2015;76(6):643-9; doi:

Gadelha MR, Ksuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20(1):10-21; doi:

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA,Beckers A. High prevalence of pituitary adenomas: across- sectional study in the province of Liege, Belgium. J ClinEndocrinol Metab 2006; 91(12):4769–75. doi:

Kwon O, Song YD, Kim SY, Lee EJ Rare Disease Study Group,Science and Research Committee, Korean Endocrine Society, Nationwide survey of acromegaly in South Korea. ClinEndocrinol (Oxf) 2013; 78(4):577–85. doi:

Holdaway IM, Rajasoorya C, Epidemiology of acromegaly. Pituitary 1999; 2(1):29–41. doi:

Nabarro JD. Acromegaly. Clin Endocrinol 1987; 26(4):481–512.

Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 2010; 72(2):203–8. doi:

Melmed S. Medical progress: Acromegaly . N Engl J Med 2006; 355(24): 2558–73. doi:

Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21(3):597–614.

Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008; 3:17. doi:

Katznelson L., Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. JCEM 2014; 99(11):3933-51. doi: doi:10.1210/jc.2014-2700.

Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright Syndrome. JCEM 2014; 99(6):1955-69. doi:

Schöfl C, Honegger J, Droste M, Grussendorf M, Finke R, Plöckinger U, et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. JCEM 2014; 99(12):E2789-E2793. doi: 10.1210/jc.2014-2094. doi:

Beckers A, Rostomyan L, Potorac I, Beckers P, Daly AF. X-LAG: How did they grow so tall? Ann Endocrinol (Paris) 2017; 78(2):131-6. doi:

Sargent J. X-linked acrogigantism – genetic characterization of a newly described paediatric growth disorder. Nat Rev Endocrinol 2015; 11(2):64. doi:

Gadelha M.R., Kasuki L., Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20:10–21. doi:




How to Cite

Vaz de Castro R, Faustino J, Ferreira F, Sampaio L. Young-onset acromegaly and gigantism: Causes and clinical features of growth hormone overproduction. REVNEC [Internet]. 2023Sep.14 [cited 2024Jun.20];32(2):103-7. Available from:



Review Articles

Most read articles by the same author(s)